Search

Crinetics Pharmaceuticals Inc

Closed

SectorHealthcare

84.67 0.28

Overview

Share price change

24h

Current

Min

84.36

Max

84.69

Key metrics

By Trading Economics

Income

7M

-121M

Sales

14M

25M

EPS

-1.14

Profit margin

-481.149

Employees

594

EBITDA

-4.7M

-131M

Recommendations

By TipRanks

Recommendations

Neutral

12 Months Forecast

+1.33% upside

Dividends

By Acuity

Next Earnings

5 Nov 2026

Market Stats

By TradingEconomics

Market Cap

63M

8.9B

Previous open

84.39

Previous close

84.67

News Sentiment

By Acuity

83%

17%

326 / 340 Healthcare

Crinetics Pharmaceuticals Inc Chart

Past performance is not a reliable indicator of future results.

Related News

14 Aug 2026, 23:52 UTC

News

Boeing Co secures over $711 million in U.S. defense contract modifications, boosting investor sentiment. Shares are higher in after-market trading.

14 Aug 2026, 23:51 UTC

News

PayPal is in advanced talks for a potential sale to Stripe and Advent, following a proposal of $60.50 per share. Shares are higher in after-market trading.

14 Aug 2026, 23:51 UTC

News

Tyson Foods will close its beef facility in Joslin, Illinois, resulting in about 2,500 job losses, as shares trade lower in after-market hours.

14 Aug 2026, 23:46 UTC

News

Replimune Group Inc shares are lower in after-market hours amid negative sentiment from a securities fraud lawsuit related to its RP1 application.

14 Aug 2026, 23:46 UTC

News

Delek US Holdings shares rose in after-market hours following Delek Logistics Partners' $230 million public offering of common units at $50.00 each.

14 Aug 2026, 23:46 UTC

News

Patterson-UTI Energy reported 98 drilling rigs operating in July. Shares rose in after-market trading, reflecting strong activity and nearing the upper end of their one-month range.

14 Aug 2026, 23:46 UTC

News

Kraft Heinz Co shares are lower in after-market trading following a $100 million marketing announcement and concerns over July's U.S. retail sales drop.

14 Aug 2026, 23:41 UTC

News

Elliott Investment Management increased its stake in Hewlett Packard Enterprise by 17.7%, contributing to higher after-market trading for the shares.

14 Aug 2026, 23:36 UTC

News

Dynatrace shares are higher in after-hours trading following Starboard Value's SEC filing disclosing an 8.9 million share stake.

14 Aug 2026, 23:31 UTC

News

Texas Pacific Land Corp shares are higher in after-market hours, with a current price of $358.89 and a market capitalization of $24.75 billion.

14 Aug 2026, 23:31 UTC

News

Jana Partners disclosed a new stake in Rapid7 Inc, acquiring over 6.7 million shares. Shares advanced during after-market hours following the announcement.

14 Aug 2026, 23:21 UTC

News

MongoDB Inc. showcases AI focus with new Atlas Managed MCP Server tools and Voyage AI features. Shares are little changed in after-market trading.

14 Aug 2026, 23:21 UTC

News

Constellation Brands shares are trading lower after Berkshire Hathaway dissolved its stake, contributing to negative sentiment amid broader weakness in the Distillers & Vintners sector.

14 Aug 2026, 23:21 UTC

News

Embecta Corp shares are lower in after-market hours amid negative sentiment from two class action lawsuits alleging securities fraud and disappointing second-quarter guidance.

14 Aug 2026, 23:11 UTC

News

Lattice Semiconductor granted over 414,000 RSUs and PRSUs to new employees as part of its equity incentive plan. Shares are trading roughly flat in after-market hours.

14 Aug 2026, 23:11 UTC

News

Lone Pine Capital LLC reduced its stake in McKesson Corp by 85.3% to 57,851 shares, contributing to the stock's decline in after-market trading.

14 Aug 2026, 23:06 UTC

News

Berkshire Hathaway raised its stake in Delta Air Lines by 44%, now holding 57.3 million shares. Shares are trading higher in after-market hours.

14 Aug 2026, 23:06 UTC

News

Mastercard proposes a plan for Brazilian payment processors to absorb R$2.5 billion in losses from Banco Master’s collapse, as shares decline in after-market trading.

14 Aug 2026, 23:06 UTC

News

Viking Global Investors has cut its stake in Walt Disney by a significant amount, while ValueAct Holdings has fully exited its position. Shares are lower in after-market trading.

14 Aug 2026, 23:02 UTC

News

Target shares lower in after-market trading despite Telsey Advisory Group's Outperform rating and raised price target to $170. Broader market weakness weighs on performance.

14 Aug 2026, 23:01 UTC

News

ServiceNow Inc shares fell in after-market trading to about $124.03 amid broader market concerns following a drop in U.S. retail sales.

14 Aug 2026, 23:01 UTC

News

Berkshire Hathaway's Form 13F filing revealed a new position in DR Horton, boosting investor interest and driving shares higher in after-hours trading.

14 Aug 2026, 23:01 UTC

News

Warner Bros Discovery Inc. shares declined in after-market hours amid regulatory scrutiny over its merger with Paramount Skydance Corp, facing opposition from state attorneys general.

14 Aug 2026, 23:01 UTC

News
Social Media

Genco Shipping & Trading shares lower in after-market trading following Diana Shipping's withdrawal of its acquisition offer, citing unrealistic demands from Genco's Board.

14 Aug 2026, 23:01 UTC

News
Social Media

Berkshire Hathaway increased its stake in Macy's to 7.3 million shares, contributing to positive sentiment as shares advanced in after-market trading.

14 Aug 2026, 23:01 UTC

News

Baker Hughes Co shares are lower in after-market hours amid rising oil and gas rig counts and concerns over a decline in U.S. retail sales.

14 Aug 2026, 23:01 UTC

News

MSCI Inc. shares are higher in after-market trading, reflecting a cumulative gain since Friday's close and a market capitalization of $41.38 billion.

14 Aug 2026, 23:01 UTC

News

Berkshire Hathaway increased its stake in New York Times Co. by 3.7%, contributing to a modest rise in after-market trading.

14 Aug 2026, 23:01 UTC

News

NIO shares rose during after-market hours to about $4.50, as options sentiment showed mixed signals ahead of the upcoming earnings report.

14 Aug 2026, 23:01 UTC

News

Realty Income Corp closed a $1.0 billion private offering of convertible senior notes, with proceeds for share repurchases and debt repayment. Shares are higher in after-market trading.

Peer Comparison

Price change

Crinetics Pharmaceuticals Inc Forecast

Price Target

By TipRanks

1.33% upside

12 Months Forecast

Average 85.56 USD  1.33%

High 95 USD

Low 80 USD

Based on 14 Wall Street analysts offering 12 month price targets forCrinetics Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Neutral

14 ratings

2

Buy

12

Hold

0

Sell

Sentiment

By Acuity

326 / 340 Healthcare

News Sentiment

Very Strong Bearish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
help-icon Live chat